X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
The funding will support a series of studies with its new drug candidate, BIO 300 (genistein), a unique, highly selective modulator of inflammation, cell cycle arrest and DNA damage repair, as a treatment for idiopathic pulmonary fibrosis.
Lead Product(s): Genistein
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO 300
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Heart, Lung, and Blood Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 24, 2023
Details:
The agreement aims to develop Humanetics' drug, BIO 300 (genistein), a unique, highly selective modulator of inflammation, cell cycle arrest and DNA damage repair, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.
Lead Product(s): Genistein
Therapeutic Area: Infections and Infectious Diseases Product Name: BIO 300
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 06, 2023
Details:
BIO 300 (genistein) is a small molecule drug candidate which increases the killing effect of radiation on multiple tumor thus selectively protect normal tissues and to avoid protection of tumor cells. It is being developed as a treatment of inflammatory pulmonary injury.
Lead Product(s): Genistein
Therapeutic Area: Infections and Infectious Diseases Product Name: BIO 300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
BIO 300 (Genistein) Oral Powder is the Company’s medical countermeasure under development to prevent acute radiation syndrome (ARS). The article details results from the trial including safety, pharmacokinetics, and biomarkers in 34 healthy volunteers.
Lead Product(s): Genistein
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BIO 300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
BIO 300 Oral Powder (Genistein) is a new formulation that was developed to address unique operational needs of military personnel and first responders. It is a solid oral dosage formulation that is shelf-stable and can be self-administered.
Lead Product(s): Genistein
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BIO 300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
The new funding will be used to create, manufacture, and test a new formulation of BIO 300 (genistein) that can be self-administered using an auto injector. Auto injectors are commonly used by the military to deliver fast-acting drugs such as atropine and naloxone.
Lead Product(s): Genistein
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BIO 300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $5.1 million Upfront Cash: Undisclosed
Deal Type: Funding June 21, 2022
Details:
BIO 300 (genistein) is an oral drug that patients self-administer daily for 12 weeks following discharge from the hospital. The primary endpoint of the trial is 12 weeks after the start of dosing and patients will be followed for one year.
Lead Product(s): Genistein
Therapeutic Area: Infections and Infectious Diseases Product Name: BIO 300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
BIO 300 is under advanced development by Humanetics as a medical countermeasure to protect healthy human tissues and organs from harm caused by ionizing radiation. BIO 300 was initially discovered by researchers at the U.S.
Lead Product(s): Genistein
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BIO 300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2021
Details:
The studies will evaluate the potential of BIO 300 to prevent metastasis of triple negative breast cancer to the lungs following radiotherapy.
Lead Product(s): Genistein
Therapeutic Area: Oncology Product Name: BIO 300
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Regenerative Medicine Minnesota
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding June 02, 2021
Details:
Partnership will support clinical trial studies of BIO 300 in COVID-19 patients.
Lead Product(s): Genistein
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO 300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Humanetics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 19, 2020
Details:
Funding will be used to conduct a placebo-controlled double-blind study to understand if 12 weeks of BIO 300 can mitigate lasting COVID-19 effects in the lungs and improve the quality of life for patients.
Lead Product(s): Genistein
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding July 23, 2020
Details:
Presentation will provide a summary of data from the recent clinical study with BIO 300 in non-small cell lung cancer patients to mitigate radiotherapy toxicity.
Lead Product(s): Genistein,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
Details:
More than 75 patients affected by COVID-19 have been successfully treated with Lactyferrin, to date with moderate to severe clinical features.
Lead Product(s): Genistein
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2020
Details:
Included in the acquisition are patents, trademarks, trade secret manufacturing processes, analytical methods, regulatory filings, and a large number of nonclinical and clinical safety studies.
Lead Product(s): Genistein
Therapeutic Area: Oncology Product Name: BIO 300
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Humanetics Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
